RAB40B

Across TCGA pan-cancer cohorts, RAB40B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAB40B data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher RAB40B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB40B expression acts as an unfavorable survival marker.

KIRP, COAD, and PAAD are the cancer types where RAB40B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.027	0.924	<.001	23	view →
COAD	OS	Median	All	0.001	0.871	<.001	18	view →
PAAD	OS	Median	All	0.131	0.613	.001	15	view →
SKCM	OS	Median	All	0.239	0.784	<.001	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAB40B–KIRP (DFS)

Open the KIRP breakdown →